Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17880548 | 0.92 | SIRT2 (0.46) | KCNQ3KCNQ2SIRT2CNR1NPC1 | |
| SCHEMBL17880534 | 0.89 | MAPT (0.48) | KCNQ3KCNQ2NPC1RAB9AMEN1 | |
| SCHEMBL17880556 | 0.88 | KCNQ3 (0.48) | KCNQ3KCNQ2CNR1NPC1RAB9A | |
| SCHEMBL17880511 | 0.87 | ALDH1A1 (0.51) | KCNQ3KCNQ2NPC1RAB9AMEN1 | |
| SCHEMBL17803520 | 0.84 | SIRT2 (0.48) | KCNQ3KCNQ2SIRT2NPC1RAB9A | |
| SCHEMBL17880508 | 0.84 | MAPT (0.44) | KCNQ3KCNQ2NPC1RAB9AMEN1 | |
| SCHEMBL17880505 | 0.84 | ESRRG (0.47) | KCNQ3KCNQ2CNR1NPC1RAB9A | |
| SCHEMBL19380321 | 0.83 | SIRT2 (0.46) | KCNQ3KCNQ2SIRT2NPC1RAB9A | |
| SCHEMBL17880555 | 0.82 | RAB9A (0.46) | KCNQ3KCNQ2NPC1RAB9AMEN1 | |
| SCHEMBL17880554 | 0.81 | NPC1 (0.49) | KCNQ3KCNQ2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9765050-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | KCNQ3 4672/4885KCNQ2 4627/4885SIRT2 262/4885 |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | HAVCR2, HCCS, NR1H4 | KCNQ3 4672/4885KCNQ2 4627/4885SIRT2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.